---
title: "Richard Lowenthal resigns from ARS Board; Sarina Tanimoto departs as CMO"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293070555.md"
description: "ARS Pharmaceuticals announced that Director Richard Lowenthal resigned and Chief Medical Officer Sarina Tanimoto departed, both effective July 15, 2026. The changes involve severance packages and prorated 2026 bonuses for both executives, conditioned on the effectiveness of release agreements. These details were disclosed in an SEC 8-K filing dated July 17, 2026."
datetime: "2026-07-17T20:03:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293070555.md)
  - [en](https://longbridge.com/en/news/293070555.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293070555.md)
generator: "portal-rs"
---

# Richard Lowenthal resigns from ARS Board; Sarina Tanimoto departs as CMO

**ARS Pharmaceuticals saw director Richard Lowenthal resign from the board and Chief Medical Officer Sarina Tanimoto leave the company, both effective July 15, 2026, with severance and prorated bonus payments agreed.**

Individual

Richard Lowenthal

Sarina Tanimoto, M.D.

Role

Member of the Board of Directors

Chief Medical Officer

Type of Change

Resigned

Terminated without cause / Ceased employment

Effective Date

July 15, 2026

July 15, 2026

Reason

Resignation was a condition to receive severance under his employment agreement and the Company's Change in Control and Severance Benefit Plan

Termination without cause

Replacement Info

Not disclosed

Not disclosed

Background Details

Referenced employment agreement and Change in Control and Severance Benefit Plan per Proxy Statement dated April 29, 2026

Served as Chief Medical Officer (no additional background disclosed)

Board/Committee Role Changes

Not disclosed

Not disclosed

Severance / Additional Payment

Severance per Proxy Statement plus one-time prorated 2026 bonus payment of $217,350, conditioned on release effectiveness

Severance per Proxy Statement plus one-time prorated 2026 bonus payment of $111,780, conditioned on release effectiveness

Original SEC Filing: ARS Pharmaceuticals, Inc. \[ SPRY \] - 8-K - Jul. 17, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [SPRY.US](https://longbridge.com/en/quote/SPRY.US.md)

## Related News & Research

- [20:01 ETSPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit](https://longbridge.com/en/news/296036090.md)
- [Flexsteel Q4 2026 Earnings Preview](https://longbridge.com/en/news/296031749.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [Baker Hughes declares Q3 2026 dividend of R$ 0.81 per unit](https://longbridge.com/en/news/296392545.md)
- [Agriculture & Natural Solutions Acquisition Received Notice of Delisting](https://longbridge.com/en/news/296272312.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**